So far, inhibitors of EZH2 seem to have the greatest potential of being used in adjuvant therapy, as EZH2 has been associated with tumor growth, metastasis and angiogenesis in several studies both in vivo and in vitro (Li R. G. et al., 2021). This evidence concerns the gene EZH2 and neoplasm.